baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

Neurocrine Biosciences/ US64125C1099 /

9/6/2024 5:51:18 PM	Chg. -1.27	Volume	Bid-	Ask-	High	Low
120.03USD	-1.05%	20,630 Turnover: 2.5 mill.	-Bid Size: -	-Ask Size: -	122.50	120.00

GlobeNewswire 9/2 Nxera Pharma to Receive US$35 Million from Neurocrine Biosciences upon Positive Phase 2 Data for Par...

GlobeNewswire 8/29 Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire 8/29 Voyager Therapeutics to Present at Multiple Upcoming Investor Conferences

GlobeNewswire 8/28 Nxera Pharma Notes Positive Phase 2 Data for Partnered Schizophrenia Candidate NBI-1117568

GlobeNewswire 8/9 Nxera Pharma Operational Highlights and Consolidated Results for the Second Quarter and First Half 2...

GlobeNewswire 8/8 Xenon Reports Q2 2024 Financial Results and Business Update

GlobeNewswire 8/7 Voyager Therapeutics to Present at Canaccord Genuity 44th Annual Growth Conference & Private Company...

GlobeNewswire 8/6 Voyager Therapeutics Reports Second Quarter 2024 Financial and Operating Results

GlobeNewswire 7/30 Voyager Therapeutics Announces Second Quarter 2024 Conference Call and Webcast

GlobeNewswire 7/23 Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire 7/9 Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire 6/13 Voyager Therapeutics to Present at Multiple Virtual Investor Conferences

GlobeNewswire 6/13 Voyager Therapeutics Announces Appointment of Nathan Jorgensen as Chief Financial Officer

GlobeNewswire 5/16 Voyager Therapeutics Announces First Participants Dosed in Single Ascending Dose Trial of VY-TAU01 f...

GlobeNewswire 5/13 Voyager Therapeutics Reports First Quarter 2024 Financial and Operating Results

GlobeNewswire 5/9 Xenon Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update

GlobeNewswire 5/9 Nxera Pharma’s partner Neurocrine Biosciences Initiates Phase 1 Clinical Study Evaluating Effects of...

GlobeNewswire 5/9 Nxera Pharma Operational Highlights and Consolidated Results for the First Quarter 2024

GlobeNewswire 5/8 Voyager Therapeutics Presents Data for Second-Generation, TRACER™-Generated Capsids and CNS Gene The...

GlobeNewswire 5/6 Voyager Therapeutics Announces First Quarter 2024 Conference Call and Webcast

GlobeNewswire 4/22 Voyager Therapeutics to Present Broad Set of Translational Data Supporting IV-Delivered, CNS Gene Th...

GlobeNewswire 4/16 Sentia Medical Sciences and Neurocrine Biosciences Extend Research Collaboration to Discover Novel C...

GlobeNewswire 4/16 Voyager Therapeutics Announces Selection of Development Candidate for GBA1 Program in Collaboration ...

GlobeNewswire 4/16 Nxera Pharma Notes Successful Development Progress of Partnered Schizophrenia Candidate NBI-1117568

GlobeNewswire 3/26 Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Neurocrine Biosciences/ US64125C1099 /

If you wish to receive reply to your feedback, please provide your email address.